• In the first quarter of 2026, Teladoc Health reported sales of US$613.85 million versus US$629.37 million a year earlier, with net loss narrowing to US$63.84 million and loss per share improving to US$0.36 from US$0.53.
• Alongside this, the company issued cautious 2026 revenue guidance and highlighted ongoing pressure in its BetterHelp mental health unit despite some progress in Integrated Care and cost efficiencies.
• We’ll now examine how Teladoc’s wider-than-expected adjusted loss and cautious BetterHelp outlook affect its existing investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Teladoc Health Investment Narrative Recap

To own Teladoc, you need to believe virtual care can scale into a durable, profitable platform despite BetterHelp’s growing pains and ongoing net losses. The key near term catalyst remains Teladoc’s push to improve profitability in Integrated Care and across the group, while the largest risk is sustained pressure in BetterHelp’s cash pay and insurance mix. This quarter’s wider adjusted loss and cautious BetterHelp outlook reinforce that risk but do not fundamentally change the long term thesis.

The most relevant disclosure here is Teladoc’s 2026 revenue guidance of US$2,481 million to US$2,576 million, alongside Q2 guidance of US$597 million to US$626 million. Set against a modest year over year revenue decline in Q1 and narrowing net losses, this framework highlights management’s expectation of continued BetterHelp pressure, partially offset by Integrated Care progress and cost efficiencies, which investors can weigh against their own views on Teladoc’s ability to scale virtual care profitably over time.

Yet investors should be aware that BetterHelp’s ongoing shift toward lower margin insurance revenue could...

Teladoc Health’s narrative projects $2.6 billion revenue and $164.1 million earnings by 2029. This assumes fairly flat yearly revenue growth and a $364.4 million earnings increase from -$200.3 million today.

Uncover how Teladoc Health's forecasts yield a $7.12 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were modeling revenue around US$2.7 billion and positive earnings by 2029, which contrasts sharply with today’s BetterHelp driven margin uncertainty and shows how widely your view on Teladoc’s future profitability can differ from others.

Explore 4 other fair value estimates on Teladoc Health - why the stock might be worth as much as 90% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.